Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA DSCAMAS1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 6/Februay/2019, 11.11 pm

Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA PCGEM decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 6/February/2019, 11.00 pm
February 6, 2019
Combinatorial therapy for targeting cancer stem cells in Myeloid leukaemia (ML): a pharmaceutical mixture encompassing Metformin and Navitoclax/ABT-263  inhibits cytosolic aminotransferase BCAT1 expression, increases a-ketoglutarate levels, promotes degradation of HIF1a levels, increases DNA demethylase levels, promotes hypomethylation, increases the expression of tumor suppressor genes, inhibits leukaemia-initiating potential of AML cells, promotes differentiation of AML cells, and inhibits cancer progression in AML, via up-regulation of its target gene, 6/February/2019, 11.22 pm
February 6, 2019
Show all

Introduction: What they say:

A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, California 94305, USA Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, California 94305, USA; Center for Tissue Regeneration, Repair and Restoration, V.A. Palo Alto Healthcare System, Palo Alto, California 94304, USA shows that “Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. This research paper was published, in the 19 April 2017 issue of the journal “Nature” [One of the best research journals in General sciences with an I.F of 43+], by Prof. Wyss-Coray, Castellano JM and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA DSCAMAS1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes


What is known?

Prof.Tony Wyss-Coray’s research team has recently shown that:  (1) human cord plasma treatment promotes cognitive and learning function in aged mice; (2) blood-borne component Tissue inhibitor of metalloproteinases 2 (TIMP2) is enriched in human cord plasma, young mouse plasma, and young mouse hippocampi; (3) TIMP2 increases hippocampal-dependent cognition; and (4) treating brain slices with TIMP2 antibody inhibits long-term potentiation and prevents hippocampal function, suggesting that increasing the expression of TIMP2 in aged individuals may enhance learning and memory.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, LncRNA DSCAMAS1  may aid in the improvement of learning, memory, and cognition.  LncRNA DSCAMAS1, by increasing the expression of its target genes, may increase the levels of TIMP2. Thereby, it may: (1) increase the expression of genes that promote learning and memory; (2) cognition and learning; (3) improve spatial memory; and (4) promote hippocampal function (fig.1).

Figure1. Mechanistic insights into how  LncRNA DSCAMAS1 functions as a positive regulator of learning, cognition, memory, and longevity. LncRNA SNHG1, by increasing the expression of TIMP2, it increases learning and memory in aged individuals

Figure 2. LncRNA DSCAMAS1 functions as learning/memory/cognitive/longevity-enhancer through induction of TIMP2

[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing “LncRNA DSCAMAS1 or its activators, either alone or in combination with other drugs, may be used to suppress the age-associated overall physiological decline of hippocampal function and improve cognition and memory (fig.2).


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does  LncRNA DSCAMAS1  increase the levels of TIMP2?

Amount: $500#

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L.,  Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA DSCAMAS1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 6/Februay/2019, 11.11 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at admin@genomediscovery.org

Comments are closed.